Ems
Clinical trials sponsored by Ems, explained in plain language.
-
New combo pill aims to simplify diabetes care
Disease control Recruiting nowThis Phase 3 trial tests a new combination pill called Madalena association for people with type 2 diabetes whose blood sugar is not well controlled with two other diabetes drugs. About 270 adults will receive either the new combo pill, standard medications, or placebos to see wh…
Phase: PHASE3 • Sponsor: EMS • Aim: Disease control
Last updated Jun 25, 2026 03:07 UTC
-
One pill to tackle diabetes and cholesterol? new trial underway
Disease control Recruiting nowThis phase 3 trial tests a new combination pill called Berlim 25/20, which contains two medicines: empagliflozin (for diabetes) and rosuvastatin (for cholesterol). The study aims to see if this single pill can better control blood sugar and LDL cholesterol in people with type 2 d…
Phase: PHASE3 • Sponsor: EMS • Aim: Disease control
Last updated Jun 25, 2026 03:07 UTC
-
New diabetes combo aims to lower blood sugar in phase 3 trial
Disease control Recruiting nowThis study tests a new drug combination called Piemonte association for people with type 2 diabetes whose blood sugar is not well controlled with current treatments. About 480 adults will receive either the new combination or a placebo to see if it safely lowers blood sugar level…
Phase: PHASE3 • Sponsor: EMS • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New hair lotion aims to thicken thinning hair in men
Disease control Recruiting nowThis study tests a new hair lotion (Finlândia) for men with male pattern baldness. About 190 men aged 18 to 60 who already use minoxidil will use the lotion for 6 months. Researchers will check if it increases hair density and monitor for side effects.
Phase: PHASE3 • Sponsor: EMS • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New drug aims to ease menstrual cramps in major trial
Symptom relief Recruiting nowThis Phase 3 trial tests an experimental drug called CDE100 for menstrual cramp pain in women with primary dysmenorrhea. About 238 women aged 16-35 will be randomly assigned to receive either CDE100 or an active comparator (Buscopan Composto) and then switch treatments. The main …
Phase: PHASE3 • Sponsor: EMS • Aim: Symptom relief
Last updated Jun 24, 2026 11:06 UTC